Last reviewed · How we verify
Rogers Center for Research & Training, Inc. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Luvox CR | Luvox CR | marketed | Selective serotonin reuptake inhibitor (SSRI) | Serotonin transporter (SERT) | Psychiatry / Mental Health |
Therapeutic area mix
- Psychiatry / Mental Health · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Centre Hospitalier Universitaire Dijon · 1 shared drug class
- Daiichi Sankyo Co., Ltd. · 1 shared drug class
- Fundació Sant Joan de Déu · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- Guangdong Provincial People's Hospital · 1 shared drug class
- Janssen Research & Development, LLC · 1 shared drug class
- Johns Hopkins University · 1 shared drug class
- AstraZeneca · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Rogers Center for Research & Training, Inc.:
- Rogers Center for Research & Training, Inc. pipeline updates — RSS
- Rogers Center for Research & Training, Inc. pipeline updates — Atom
- Rogers Center for Research & Training, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Rogers Center for Research & Training, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/rogers-center-for-research-training-inc. Accessed 2026-05-16.